Editorial & Opinion
Spoiled for Choice: P2Y 12 Receptor Inhibition in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
| العنوان: | Spoiled for Choice: P2Y |
|---|---|
| المؤلفون: | Sibbing D; Privatklinik Lauterbacher Mühle am Ostersee, Seeshaupt, Germany; Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. Electronic address: dirk@sibbing.net., Massberg S; Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany., Rizas KD; Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. |
| المصدر: | JACC. Cardiovascular interventions [JACC Cardiovasc Interv] 2024 Jun 10; Vol. 17 (11), pp. 1371-1373. |
| نوع المنشور: | Editorial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101467004 Publication Model: Print Cited Medium: Internet ISSN: 1876-7605 (Electronic) Linking ISSN: 19368798 NLM ISO Abbreviation: JACC Cardiovasc Interv Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York : Elsevier |
| مواضيع طبية MeSH: | Atrial Fibrillation*/physiopathology , Atrial Fibrillation*/drug therapy , Atrial Fibrillation*/diagnosis , Percutaneous Coronary Intervention*/adverse effects , Purinergic P2Y Receptor Antagonists*/therapeutic use , Purinergic P2Y Receptor Antagonists*/adverse effects, Humans ; Treatment Outcome ; Risk Factors ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Clinical Decision-Making ; Coronary Artery Disease/therapy ; Coronary Artery Disease/diagnostic imaging ; Risk Assessment ; Hemorrhage/chemically induced |
| مستخلص: | Competing Interests: Funding Support and Author Disclosures Dr Sibbing has received speaker fees and fees for advisory board activities from Bayer, Daiichi-Sankyo, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. |
| فهرسة مساهمة: | Keywords: antithrombotic therapy; atrial fibrillation; escalated P2Y(12) inhibition; percutaneous coronary intervention |
| المشرفين على المادة: | 0 (Purinergic P2Y Receptor Antagonists) 0 (Platelet Aggregation Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240612 Date Completed: 20240612 Latest Revision: 20240625 |
| رمز التحديث: | 20240625 |
| DOI: | 10.1016/j.jcin.2024.04.030 |
| PMID: | 38866459 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1876-7605 |
|---|---|
| DOI: | 10.1016/j.jcin.2024.04.030 |